{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Duloxetine+%28Oral+Antidepressant%29&page=2",
    "query": {
      "intervention": "Duloxetine (Oral Antidepressant)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Duloxetine+%28Oral+Antidepressant%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Duloxetine+%28Oral+Antidepressant%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T19:13:56.530Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02497287",
      "title": "A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment-resistant Depression"
      ],
      "interventions": [
        {
          "name": "Esketamine (Intranasal Spray)",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Sertraline (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 802,
      "start_date": "2015-09-30",
      "completion_date": "2017-10-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 16,
      "location_summary": "New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497287"
    },
    {
      "nct_id": "NCT02417064",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment-resistant Depression"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram (Oral antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Sertraline (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 346,
      "start_date": "2015-08-10",
      "completion_date": "2018-02-20",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02417064"
    },
    {
      "nct_id": "NCT01288079",
      "title": "A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "TC-5214",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 145,
      "start_date": "2011-02",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2012-11-20",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 25,
      "location_summary": "Beverly Hills, California • Chino, California • Garden Grove, California + 22 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01288079"
    },
    {
      "nct_id": "NCT07795593",
      "title": "Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Painful Diabetic Neuropathy (PDN)",
        "Diabetic Nephropathies"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy (CBT)",
          "type": "DEVICE"
        },
        {
          "name": "Oral Medication",
          "type": "DRUG"
        },
        {
          "name": "Topical Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2026-10",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 23,
      "location_summary": "Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07795593"
    },
    {
      "nct_id": "NCT01436175",
      "title": "SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "SPD489 (Lisdexamfetamine dimesylate) + Antidepressant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1570,
      "start_date": "2012-02-27",
      "completion_date": "2014-03-27",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 140,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carson",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436175"
    },
    {
      "nct_id": "NCT04965272",
      "title": "A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Cariprazine 0.75 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Cariprazine 1.5 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Cariprazine 3.0 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-08-18",
      "completion_date": "2021-08-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 36,
      "location_summary": "Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04965272"
    },
    {
      "nct_id": "NCT01469377",
      "title": "Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cariprazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 819,
      "start_date": "2011-12-15",
      "completion_date": "2013-12-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-01",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 39,
      "location_summary": "Garden Grove, California • National City, California • Oceanside, California + 34 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01469377"
    },
    {
      "nct_id": "NCT02493868",
      "title": "A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram (Oral antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Sertraline (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 719,
      "start_date": "2015-10-01",
      "completion_date": "2018-02-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02493868"
    },
    {
      "nct_id": "NCT02422186",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Sertraline (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine Extended Release (XR) (New Antidepressant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2015-08-20",
      "completion_date": "2017-08-10",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 15,
      "location_summary": "San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422186"
    },
    {
      "nct_id": "NCT04476030",
      "title": "A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "SAGE-217",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sertraline",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Citalopram",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Desvenlafaxine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 440,
      "start_date": "2020-11-09",
      "completion_date": "2021-12-22",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-09T19:13:56.530Z",
      "location_count": 51,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04476030"
    }
  ]
}